8-K: FOXO Technologies Announces Special Shareholder Meeting to Approve Key Financial Proposals

FOXO Technologies has scheduled a special shareholder meeting on November 29, 2024, to vote on proposals including a potential reverse stock split, debt-to-equity conversions, and an equity line of credit.

Summary

• FOXO Technologies Inc. has announced a Special Meeting of Shareholders to be held virtually on November 29, 2024, at 10:30 am Eastern Time.
• The meeting will address several key proposals, including a potential reverse stock split with a ratio between 1:5 and 1:100, to be determined by the Board of Directors.
• Shareholders will also vote on the approval of issuing shares to a debt holder in exchange for approximately $1.945 million in outstanding debt as of September 30, 2024.
• The company seeks approval for issuing shares related to a $5 million Equity Line of Credit with ClearThink Capital Partners, LLC.
• Additionally, shareholders will vote on the issuance of shares related to a $2.8 million debt funding agreement with an institutional investor, of which $1 million has already been received.
• The company is also seeking approval to adjourn the meeting if necessary to solicit additional proxies.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including the need for a reverse stock split, debt-to-equity conversion, and reliance on an equity line of credit. While the company is taking steps to address these issues, the overall tone suggests a precarious financial situation.

Positives

• The company is actively addressing its debt obligations by proposing a debt-to-equity swap.
• The establishment of a $5 million Equity Line of Credit provides potential financial flexibility.
• The company has secured $1 million in debt funding, with a potential for an additional $1.8 million.
• The company is taking steps to maintain its NYSE American listing by addressing the minimum share price requirement.

Negatives

• The company is considering a reverse stock split, which can be a sign of financial distress.
• The company has been unable to repay a debt holder, necessitating a debt-to-equity swap.
• The company needs shareholder approval to issue a significant number of shares, potentially diluting existing shareholders.
• The company is relying on an equity line of credit, which may indicate a need for additional funding.

Risks

• The reverse stock split may negatively impact investor perception of the company.
• The issuance of a large number of shares could dilute existing shareholders' ownership.
• The company's reliance on debt and equity financing may indicate underlying financial challenges.
• There is a risk that the company may not be able to draw on the equity line of credit if needed.
• The company's share price could fall below the $0.10 minimum requirement for NYSE American continued listing requirements.

Future Outlook

The company plans to hold an Annual General Meeting for 2024 in the coming weeks, and is focused on building FOXO into a successful company.

Management Comments

• We have had a productive year to date and continue to take all steps necessary to ensure we build FOXO into a successful company, said Mark White, Interim CEO of FOXO.
• We look forward to the continued support of our shareholders and ask that they support the approvals requested.

Industry Context

The company's actions, such as the potential reverse stock split and debt-to-equity conversion, are not uncommon for companies facing financial challenges or seeking to maintain listing compliance. The biotechnology industry is highly competitive and regulated, requiring companies to actively manage their financial positions.

Comparison to Industry Standards

• Reverse stock splits are often used by companies with low share prices to maintain listing requirements, similar to actions taken by other small-cap companies facing delisting risks.
• Debt-to-equity swaps are a common method for companies to reduce debt burdens, especially when facing difficulties in repayment, similar to strategies used by other companies in financial distress.
• Equity lines of credit are a common financing tool for companies seeking flexible access to capital, similar to other companies in the biotechnology and healthcare sectors.
• The need for shareholder approval for significant share issuances is standard practice for companies listed on exchanges like NYSE American, ensuring transparency and shareholder involvement.

Stakeholder Impact

• Shareholders may experience dilution if the proposed share issuances are approved.
• Shareholders may experience a decrease in share price if the reverse stock split is implemented.
• Creditors may benefit from the debt-to-equity swap.
• The company's employees may be impacted by the company's financial situation.

Next Steps

• Shareholders will vote on the proposed resolutions at the Special Meeting on November 29, 2024.
• The company will determine the exact ratio for the reverse stock split if approved.
• The company will proceed with the debt-to-equity swap if approved.
• The company will draw on the equity line of credit as needed, if approved.
• The company will hold an Annual General Meeting for 2024 in the coming weeks.

Key Dates

Keywords

Shareholder Meeting, Reverse Stock Split, Debt-to-Equity Swap, Equity Line of Credit, NYSE American, Share Issuance, Debt Funding, Financial Proposals